This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Incentive Sensitivity as a Behavioral Marker of Clinical Remission From Major Depressive Episode

Thomas Mauras, MD; Marc Masson, MD; Philippe Fossati, PhD, MD; and Mathias Pessiglione, PhD

Published: June 22, 2016

Article Abstract

Background: Reduction of goal-directed behaviors is frequently observed in depression and may be linked to dysfunction of incentive motivation process.

Objective: To investigate whether incentive sensitivity could constitute a behavioral marker of clinical remission in major depression.

Methods: A handgrip force measurement device was employed to assess the impact of incentive motivation and emotional manipulation on the effort produced by remitted patients (n = 20) compared to matched depressed patients (n = 22) and healthy controls (n = 26). Depressed and remitted patients fulfilled the major depressive disorder DSM-IV criteria for current episode and remission state, respectively. The study was performed between March and July 2013.

Results: Relative to patients with acute depression, patients after remission retrieved a normal sensitivity to incentives (t1,40 = 4.18, P < 1.5 × 10−4), but relative to healthy controls, they kept an abnormally high susceptibility to emotional arousal (t1,44 = 2.4, P = .02). Normalization of incentive sensitivity exhibited in the behavioral test was associated with improvement of apathy measured on the clinical scale.

Conclusions: Using a simple behavioral paradigm at patients’ bedside, we could identify the factors influencing effort production, so as to discriminate remitted patients from both depressed patients and healthy controls.

Volume: 77

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...